STAT

FEBRUARY 13, 2024

Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV.

FDA 106

FDA 106

STAT

FEBRUARY 12, 2024

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

111

111

STAT

MAY 3, 2024

 Earlier this year, a state appeals court ruled the company could be held liable for halting further development of an HIV medicine that was safer than an HIV drug it was already selling. Topline data are expected late this year.

Documentation 80

Documentation 80

STAT

JUNE 22, 2023

government asked a federal judge to overturn a recent case in which a jury decided that Gilead Sciences did not infringe on patents held by the Centers for Disease Control and Prevention for a pair of groundbreaking HIV pills. Moreover, the drug company insisted that it acted in good faith during its negotiations with the government.

81

81

STAT

FEBRUARY 17, 2023

Christi Shaw, the CEO of Gilead’s Kite Pharmaceuticals cell therapy unit, is leaving the company, Gilead said Friday in a statement. Under her leadership, the once-embattled division, which makes personalized CAR-T treatments for blood cancers, has begun to be a significant contributor to Gilead’s overall business.

78

78

STAT

JUNE 30, 2023

In a setback to AIDS activists, a federal court jury on Friday cleared Gilead Sciences and Teva Pharmaceuticals of allegations that the companies struck an illegal deal that inflated prices for HIV medicines. A lawsuit filed four years ago accused Gilead of using a range of controversial business tactics that led the U.S.

71

71

STAT

DECEMBER 1, 2022

Gilead Sciences won a key round in its battle with the U.S. As part of a broader fight with the agency over research and resulting patent rights to the medication, the company had filed a lawsuit in 2020 alleging the CDC violated the terms of a 15-year-old collaboration. Continue to STAT+ to read the full story…

103

103

STAT

JANUARY 25, 2024

We also take a look at Gilead Sciences’ struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm. We discuss how biotech’s downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. Read the rest…

82

82

Fierce Pharma

JULY 5, 2023

Gilead and Teva have chalked up an important legal victory in a California court, defeating allegations that they created an anticompetitive scheme to delay generic competition to lucrative HIV tre | Gilead and Teva were accused of conspiring to keep HIV generics off the market in a 2019 lawsuit seeking $3.6 billion in damages.

64

64

pharmaphorum

JANUARY 20, 2022

US pharma giant Gilead Sciences has accused a network of unauthorised suppliers and distributors of selling more than $250 million of counterfeit versions of its HIV medications. ” The post Gilead takes legal action against counterfeit HIV drug network appeared first on.

Documentation 109

Documentation Labelling FDA 109

Fierce Pharma

OCTOBER 4, 2023

The Federal Trade Commission (FTC) recently came up short in its attempt to derai | More than 30 companies and biopharma associations have introduced the Partnership for the US Life Science Ecosystem (PULSE) to increase awareness of the value of M&A. AbbVie, Gilead, Merck and Novartis also are in the fold.

86

86

European Pharmaceutical Review

JANUARY 4, 2023

EVOQ Therapeutics Inc has agreed to license its NanoDisc technology for rheumatoid arthritis (RA) and lupus to Gilead Sciences, Inc, enabling EVOQ to potentially receive up $658.5 The companies will collaborate to advance preclinical development and Gilead will be responsible for clinical development and commercialisation.

Immunization 93

Immunization 93

European Pharmaceutical Review

OCTOBER 21, 2022

According to a new exclusive option and collaboration agreement between Gilead Sciences, Inc. and MacroGenics, Gilead will use MacroGenics’ DART® platform to develop MGD024, a potential therapy for blood cancers. Under the deal, Gilead will pay MacroGenics an initial $60 million. MacroGenics will be entitled up to $1.7

85

85

pharmaphorum

AUGUST 3, 2022

Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first time in the second quarter. Gilead acquired the drug as part of its $21 billion takeover of Immunomedics in 2020. Gilead’s HIV portfolio meanwhile brought in $4.2

Vaccines 100

Vaccines 100

Pharmaceutical Technology

MAY 10, 2023

Gilead Sciences has acquired biotech company XinThera in an effort to bolster its oncology and inflammation pipeline. Gilead Sciences stated that the two programmes have the potential to address a number of indications and to provide development opportunities both alone and along with its wider portfolio.

Immunization 52

Immunization 52

Fierce Pharma

NOVEMBER 8, 2023

With the goal of becoming a powerhouse in oncology, Gilead Sciences is closely tracking the progress of its two marketed CAR-T therapies. | The company attributes the gradual pace of CAR-T uptake to the "fragmentation" of the U.S. healthcare system, Kite head Cindy Perettie said on an earnings call.

68

68

pharmaphorum

SEPTEMBER 24, 2020

Gilead has paid $97 million to resolve claims by US authorities that it acted illegally by using a charitable foundation as a conduit to fund co-payments of thousands of Medicare patients taking its pulmonary arterial hypertension drug, Letairis. Gilead does not believe it violated the law and had no intention of doing so.

Insurance 98

Insurance 98

STAT

MAY 10, 2023

jury handed a major win to Gilead Sciences in a closely watched battle with the U.S.  The jury decided Gilead did not infringe on patents held by the Centers for Disease Control and Prevention and, in fact, that the patents were invalid.   The We are wired to accept telegrams and postcards, too. … A U.S.

Pharmaceutical Companies 79

Pharmaceutical Companies Pharmaceutical Companies 79

STAT

SEPTEMBER 15, 2022

In a victory for Gilead Sciences, Brazilian antitrust authorities dismissed a complaint filed by several advocacy groups that alleged the company charged “abusive” prices for a hepatitis C treatment.

Documentation 81

Documentation 81

Outsourcing Pharma

OCTOBER 4, 2022

The company announces further measures against a counterfeiting network it accused of being responsible for selling illegitimate Gilead HIV medications.

77

77

Pharmaceutical Technology

AUGUST 23, 2022

Gilead Sciences has obtained the European Commission (EC) marketing authorisation for Sunlenca (lenacapavir) injection and tablets to treat human immunodeficiency virus (HIV) infection. Earlier this month, the company entered a definitive agreement to acquire MiroBio for nearly $405m.

FDA 119

FDA 119

pharmaphorum

AUGUST 5, 2022

The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women and minority communities in their businesses, but are they meeting those diversity objectives? Image by Gino Crescoli from Pixabay .

98

98

Pharmaceutical Technology

JANUARY 4, 2023

Gilead Sciences has entered a collaboration and licensing agreement with EVOQ Therapeutics to advance the latter’s technology and develop immunotherapies to treat rheumatoid arthritis (RA) and lupus. Under the deal terms, the two companies will work together to advance the preclinical development of RA and lupus immunotherapies.

Immunization 52

Immunization 52

Pharmafile

MARCH 13, 2023

Gilead Sciences, a research-based biopharmaceutical company, has won again in the lawsuit levelled against clinics, prescribers, medical labs and pharmacies in relation to fraudulent claims for HIV medications. read more

52

52

European Pharmaceutical Review

JULY 12, 2022

According to a recent survey of patient groups, Roche, Pfizer, ViiV Healthcare and Gilead Sciences are among the top companies for implementing and reporting progress on environmental, social, governance (ESG) activities.

Communication 96

Communication 96

Fierce Pharma

AUGUST 4, 2023

For years, Gilead has been on a mission to become a power player in oncology. | The company is sticking to its ambitions of pulling a third of its revenue from its oncology portfolio by 2030. This year, the company expects $3 billion to come from its cancer trio of Trodelvy, Tecartus and Yescarta.

52

52

Pharmaceutical Technology

JULY 25, 2023

Gilead Sciences and IT company Cognizant have announced an expansion of their collaboration to expedite digital transformation.

52

52

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. GS-6791 is the first development candidate from the previous collaboration between Gilead Sciences and Nurix in 2019.

52

52

European Pharmaceutical Review

AUGUST 10, 2022

Gilead Sciences has signed a definitive agreement to acquire outstanding share capital of clinical-stage biotechnology company MiroBio for around $405 million. Gilead said it anticipates advancing additional agonists derived from the I-ReSToRE platform over the “next several years.”

Immunization 84

Immunization 84

Pharmaceutical Technology

DECEMBER 28, 2022

Gilead Sciences and Jounce Therapeutics have amended their current license agreement for first-in-class immunotherapy, GS-1811 (formerly JTX-1811). The amended agreement will allow Gilead Sciences to acquire all the remaining rights for GS-1811 from Jounce Therapeutics. The initial license agreement was signed in 2020.

Immunization 52

Immunization 52

pharmaphorum

AUGUST 5, 2022

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal. The post Gilead snaps up MiroBio and its checkpoint agonists for $405m appeared first on.

Immunization 94

Immunization 94

PharmaShots

MAY 15, 2023

Shots: The companies expand their May 2020 collaboration to include inflammatory disease therapies. Your go-to media platform for customized news ranging for multiple indications.

40

40

STAT

MAY 4, 2023

Gilead Sciences is famous — or perhaps, notorious — for its cure for hepatitis C. But the pharma giant believes the foundation of its company will continue to be its HIV franchise, particularly the pre-exposure prophylaxis (PrEP) drugs that help prevent the infection.

93

93

pharmaphorum

JULY 5, 2022

The big pharma is paying $100 million upfront for the company, and offering up to $805 million in milestone payments if TeneoTwo’s drug candidates meet development objectives, plus up to $360 million if they hit sales targets. AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27

Immunization 124

Immunization 124

pharmaphorum

APRIL 20, 2022

Gilead has won a crucial court order in a wide-ranging lawsuit against a network of clinics, prescribers, medical labs and pharmacies in Florida that it claims have been making fraudulent reimbursement claims for HIV medicines. The post Gilead wins court order against fraudsters targeting HIV programme appeared first on.

Insurance 69

Insurance 69

pharmaphorum

FEBRUARY 2, 2022

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 The litigation extends back to 2018, when ViiV – a joint venture majority owned by GlaxoSmithKline alongside Pfizer and Shionogi – accused Gilead of infringing its patents on HIV integrase inhibitor dolutegravir.

Compounding 72

Compounding FDA 72

STAT

FEBRUARY 16, 2024

insurance claims data compiled by health technology company Komodo Health. Just a week after dropping the development of a treatment for blood cancers, Gilead Sciences has paused enrollment in clinical trials of the same drug in solid tumors, adding to concerns about its side effects , Pharmaphorum explains. The  The U.S.

Insurance 79

Insurance 79